CD86 demonstrated to be an unfavorable factor independent of clinicodemographic variables in tumor progression and prognosis for LGG, which was validated by qRT-PCR and WB in LGG samples, as well as a real-world cohort in CGGA. This evidence concerns the gene CD86 and neoplasm.